NASDAQ: LGND
Ligand Pharmaceuticals Inc Stock

$254.57+6.33 (+2.55%)
Updated Jun 11, 2026
LGND Price
$254.57
Fair Value Price
$69.59
Market Cap
$5.10B
52 Week Low
$110.00
52 Week High
$258.57
P/E
32.22x
P/B
5.12x
P/S
14.46x
PEG
1.62x
Dividend Yield
N/A
Revenue
$274.48M
Earnings
$153.56M
Gross Margin
95.3%
Operating Margin
69.4%
Profit Margin
55.9%
Debt to Equity
0.54
Operating Cash Flow
$123M
Beta
1.14
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A

LGND Overview

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LGND's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
LGND
Ranked
#158 of 463

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$236.17A
$53.50A
$15.85A
View Top Biotech Stocks

Be the first to know about important LGND news, forecast changes, insider trades & much more!

LGND News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LGND scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LGND ($254.57) is overvalued by 265.82% relative to our estimate of its Fair Value price of $69.59 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LGND ($254.57) is not significantly undervalued (265.82%) relative to our estimate of its Fair Value price of $69.59 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LGND ($254.57) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LGND due diligence checks available for Premium users.

Valuation

LGND fair value

Fair Value of LGND stock based on Discounted Cash Flow (DCF)

Price
$254.57
Fair Value
$69.59
Overvalued by
265.82%
LGND ($254.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LGND ($254.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LGND ($254.57) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LGND price to earnings (PE)

For valuing profitable companies with steady earnings

Company
32.22x
Industry
17.66x
Market
13.95x
LGND is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LGND is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

LGND price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
5.12x
Industry
4.83x
LGND is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LGND price to earnings growth (PEG)

For valuing profitable companies with growth potential

LGND is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

LGND's financial health

Profit margin

Revenue
$51.7M
Net Income
-$13.3M
Profit Margin
-25.8%
LGND's Earnings (EBIT) of $190.48M... subscribe to Premium to read more.
Interest Coverage Financials
LGND's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.5B
Liabilities
$534.8M
Debt to equity
0.54
LGND's short-term assets ($865.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LGND's short-term assets ($865.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LGND's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LGND's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$48.7M
Investing
-$94.3M
Financing
-$14.1M
LGND's operating cash flow ($123.50M)... subscribe to Premium to read more.
Debt Coverage Financials

LGND vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LGNDC$5.10B+2.55%32.22x5.12x
CAIC$5.09B+4.90%-2.87x8.57x
CGOND$5.08B+4.95%-24.74x4.66x
XENED$5.04B+1.66%-11.10x3.77x
SRRKD$5.36B+1.36%-12.92x19.40x

Ligand Pharmaceuticals Stock FAQ

What is Ligand Pharmaceuticals's quote symbol?

(NASDAQ: LGND) Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol LGND. Ligand Pharmaceuticals stock quotes can also be displayed as NASDAQ: LGND.

If you're new to stock investing, here's how to buy Ligand Pharmaceuticals stock.

What is the 52 week high and low for Ligand Pharmaceuticals (NASDAQ: LGND)?

(NASDAQ: LGND) Ligand Pharmaceuticals's 52-week high was $258.57, and its 52-week low was $110.00. It is currently -1.55% from its 52-week high and 131.43% from its 52-week low.

How much is Ligand Pharmaceuticals stock worth today?

(NASDAQ: LGND) Ligand Pharmaceuticals currently has 20,041,061 outstanding shares. With Ligand Pharmaceuticals stock trading at $254.57 per share, the total value of Ligand Pharmaceuticals stock (market capitalization) is $5.10B.

Ligand Pharmaceuticals stock was originally listed at a price of $77.28 in Dec 31, 1997. If you had invested in Ligand Pharmaceuticals stock at $77.28, your return over the last 28 years would have been 229.41%, for an annualized return of 4.35% (not including any dividends or dividend reinvestments).

How much is Ligand Pharmaceuticals's stock price per share?

(NASDAQ: LGND) Ligand Pharmaceuticals stock price per share is $254.57 today (as of Jun 11, 2026).

What is Ligand Pharmaceuticals's Market Cap?

(NASDAQ: LGND) Ligand Pharmaceuticals's market cap is $5.10B, as of Jun 13, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ligand Pharmaceuticals's market cap is calculated by multiplying LGND's current stock price of $254.57 by LGND's total outstanding shares of 20,041,061.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.